用卡铂加紫杉醇对无法切除的局部晚期胸腺癌进行确定性化放疗:一个病例系列

IF 0.2 Q4 ONCOLOGY
{"title":"用卡铂加紫杉醇对无法切除的局部晚期胸腺癌进行确定性化放疗:一个病例系列","authors":"","doi":"10.1016/j.cpccr.2024.100323","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy with radiotherapy has not yet been established.</p></div><div><h3>Materials and methods</h3><p>We present three cases of locally advanced thymic carcinoma treated with definitive chemoradiotherapy using carboplatin and paclitaxel.</p></div><div><h3>Results</h3><p>Three patients aged 74–81 with Masaoka stage III thymic carcinoma were included. One patient was a woman, and two patients were men. All patients received weekly carboplatin (area under the curve, 2) plus paclitaxel (40 mg m<sup>-12</sup>) and concurrent radiotherapy (60 Gy). One patient experienced an adverse event of grade 3 radiation pneumonitis after chemoradiotherapy, but the three patients completed chemoradiotherapy with minor adverse events during treatment. Progression-free survival after chemoradiotherapy was 59+, 24+, and 16+ months, respectively; all patients were alive.</p></div><div><h3>Conclusion</h3><p>Definitive concurrent chemoradiotherapy with weekly carboplatin plus paclitaxel may be effective for treating unresectable locally advanced thymic carcinomas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000462/pdfft?md5=fa9d2b295942b0387d1f7cb0dacef82f&pid=1-s2.0-S2666621924000462-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series\",\"authors\":\"\",\"doi\":\"10.1016/j.cpccr.2024.100323\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy with radiotherapy has not yet been established.</p></div><div><h3>Materials and methods</h3><p>We present three cases of locally advanced thymic carcinoma treated with definitive chemoradiotherapy using carboplatin and paclitaxel.</p></div><div><h3>Results</h3><p>Three patients aged 74–81 with Masaoka stage III thymic carcinoma were included. One patient was a woman, and two patients were men. All patients received weekly carboplatin (area under the curve, 2) plus paclitaxel (40 mg m<sup>-12</sup>) and concurrent radiotherapy (60 Gy). One patient experienced an adverse event of grade 3 radiation pneumonitis after chemoradiotherapy, but the three patients completed chemoradiotherapy with minor adverse events during treatment. Progression-free survival after chemoradiotherapy was 59+, 24+, and 16+ months, respectively; all patients were alive.</p></div><div><h3>Conclusion</h3><p>Definitive concurrent chemoradiotherapy with weekly carboplatin plus paclitaxel may be effective for treating unresectable locally advanced thymic carcinomas.</p></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666621924000462/pdfft?md5=fa9d2b295942b0387d1f7cb0dacef82f&pid=1-s2.0-S2666621924000462-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621924000462\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000462","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的胸腺癌(TC)非常罕见。对于无法切除的局部晚期胸腺癌,目前尚无治疗策略的证据。确定性放化疗可治疗这种疾病。材料与方法 我们报告了三例使用卡铂和紫杉醇进行确定性化放疗治疗的局部晚期胸腺癌病例。其中一名患者为女性,两名患者为男性。所有患者均接受每周一次的卡铂(曲线下面积为 2)加紫杉醇(40 mg m-12)治疗,并同时接受放疗(60 Gy)。一名患者在放化疗后出现了 3 级放射性肺炎的不良反应,但三名患者在完成放化疗的过程中均未出现轻微不良反应。化放疗后的无进展生存期分别为59+个月、24+个月和16+个月;所有患者均存活。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series

Objectives

Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy with radiotherapy has not yet been established.

Materials and methods

We present three cases of locally advanced thymic carcinoma treated with definitive chemoradiotherapy using carboplatin and paclitaxel.

Results

Three patients aged 74–81 with Masaoka stage III thymic carcinoma were included. One patient was a woman, and two patients were men. All patients received weekly carboplatin (area under the curve, 2) plus paclitaxel (40 mg m-12) and concurrent radiotherapy (60 Gy). One patient experienced an adverse event of grade 3 radiation pneumonitis after chemoradiotherapy, but the three patients completed chemoradiotherapy with minor adverse events during treatment. Progression-free survival after chemoradiotherapy was 59+, 24+, and 16+ months, respectively; all patients were alive.

Conclusion

Definitive concurrent chemoradiotherapy with weekly carboplatin plus paclitaxel may be effective for treating unresectable locally advanced thymic carcinomas.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信